35.26

1.84% -0.66

Newamsterdam Pharma Company Nv (NAMS)

Overview News Price History Financials Why NAMS Down? Discussions Forecast

Newamsterdam Pharma Company Nv stock is traded at $35.26, with a volume of 564.23K. It is down -1.84% in the last 24 hours and up +20.22% over the past month. NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Previous Close:

$35.92

Open:

$36.01

24h Volume:

564.23K

Relative Volume:

0.45

Market Cap:

$4.12B

Revenue:

$22.57M

Net Income/Loss:

$-212.73M

P/E Ratio:

-19.54

EPS:

-1.8045

Net Cash Flow:

$-142.19M

1W Performance:

+1.23%

1M Performance:

+20.22%

6M Performance:

+2.59%

1Y Performance:

+60.13%

1-Day Range:

$34.15

$36.17

1-Week Range:

$33.81

$37.37

52-Week Range:

$20.53

$42.20

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name

Newamsterdam Pharma Company Nv

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

35 206 2971

Address

GOOIMEER 2-35, NARRDEN

Employee

100

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

NAMS's Discussions on Twitter

Compare NAMS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NAMS Newamsterdam Pharma Company Nv	35.26	4.12B	22.57M	-212.73M	-142.19M	-1.8045
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	Truist	Buy
Oct-20-25	Resumed	H.C. Wainwright	Buy
Aug-25-25	Initiated	Wells Fargo	Overweight
Jul-17-25	Initiated	Goldman	Neutral
Jun-17-25	Initiated	Citigroup	Buy
Jun-10-25	Initiated	Stifel	Buy
Jun-04-25	Initiated	Cantor Fitzgerald	Overweight
Dec-30-24	Initiated	H.C. Wainwright	Buy
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Jan-18-24	Initiated	Guggenheim	Buy
Jan-16-24	Initiated	Piper Sandler	Overweight
Oct-30-23	Initiated	RBC Capital Mkts	Outperform

View All

Newamsterdam Pharma Company Nv Stock (NAMS) Latest News

04:21 AM

Price to sales forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView

04:21 AM

Jul 08, 2026

Responsive Playbooks and the NAMS Inflection - Stock Traders Daily

Jul 08, 2026

Jul 05, 2026

NewAmsterdam Pharma (NAMS) Alzheimer’s Data Push Puts Fair Value Back In Focus - Sahm

Jul 05, 2026

Jul 03, 2026

NAMSNewAmsterdam Pharma Company NV Latest SEC Filings - Finviz

Jul 03, 2026

Jul 02, 2026

(NAMSW) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Jul 02, 2026

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Jul 02, 2026

NewAmsterdam Pharma awards stock incentives to four new hires - Stock Titan

Jul 02, 2026

Jul 01, 2026

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026 - marketscreener.com

Jul 01, 2026

NewAmsterdam Pharma Company N.V. - TradingView

Jul 01, 2026

NewAmsterdam Pharma puts obicetrapib in Alzheimer’s spotlight at AAIC 2026 - Stock Titan

Jul 01, 2026

Jun 28, 2026

Price to sales forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView

Jun 28, 2026

Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView

Jun 28, 2026

Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView

Jun 28, 2026

Enterprise value to EBIT forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView

Jun 28, 2026

Jun 27, 2026

Price to sales forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView

Jun 27, 2026

Price to book forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView

Jun 27, 2026

Understanding the Setup: (NAMS) and Scalable Risk - Stock Traders Daily

Jun 27, 2026

Price to book forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView

Jun 27, 2026

Price to book forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView

Jun 27, 2026

NewAmsterdam Pharma Company N.V. Actuals & Estimates (NASDAQ:NAMS) - TradingView

Jun 27, 2026

NAMS Forecast — Price Target — Prediction for 2027 - TradingView

Jun 27, 2026

Jun 26, 2026

NewAmsterdam Pharma Company N.V. Actuals & Estimates (MUN:KH6) - TradingView

Jun 26, 2026

Enterprise value to EBITDA forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView

Jun 26, 2026

Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView

Jun 26, 2026

NewAmsterdam Pharma Company N.V. Actuals & Estimates (LSX:A3DUAC) - TradingView

Jun 26, 2026

Jun 25, 2026

Enterprise value to EBIT forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView

Jun 25, 2026

NewAmsterdam Pharma (NAMS) Slides 2.76% as Stock Tests Key Support LevelsRounding Bottom - dars.gov.et

Jun 25, 2026

Price to earnings forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView

Jun 25, 2026

Jun 24, 2026

NewAmsterdam Pharma (NAMS) CAO exercises options and sells 40,000 shares - Stock Titan

Jun 24, 2026

Price to earnings forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView

Jun 24, 2026